Comparison of once-daily and twice-daily ilaprazole for healing of stomach ulcers after endoscopic resection

Dose-related healing of artificial ulcers after endoscopic submucosal dissection using ilaprazole (TM noltec): A randomized controlled study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0012358

Enrollment

140

Registered

2026-07-30

Start date

2025-05-19

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : This is a prospective, randomized, parallel-group study in patients with artificial gastric ulcers following endoscopic submucosal dissection. Participants are randomly assigned to one of two t

the single dose and treatment duration are identical.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Patients aged 18 to 75 years who are scheduled to undergo endoscopic submucosal dissection for early gastric cancer or gastric adenoma measuring =15 mm. -Patients who voluntarily provide written informed consent to participate in this study.

Exclusion criteria

Exclusion criteria: -Patients with a history of hypersensitivity or allergy to the investigational drug (Noltec®) or other proton pump inhibitors (PPIs). -Patients in whom the use of the investigational drug is contraindicated because of potential drug interactions. -Patients who require continuous treatment with medications that may induce or aggravate gastric ulcers, including nonsteroidal anti-inflammatory drugs (NSAIDs), antiplatelet agents (including aspirin), or anticoagulants. -Patients with significant cardiovascular disease (New York Heart Association [NYHA] class III or IV) or significant respiratory disease. -Patients with clinically significant abnormal laboratory findings at screening, including: -Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin =2 times the upper limit of normal (ULN) at the study site; -Blood urea nitrogen (BUN) or serum creatinine =2 times the upper limit of normal (ULN) at the study site. -Patients with clinically significant abnormal electrocardiographic (ECG) findings. -Pregnant or breastfeeding women. -Patients with dementia, cognitive impairment, or impaired consciousness. -Patients who do not provide written informed consent to participate in this study. -Patients who have participated in another clinical trial within 30 days before enrollment in this study. -Patients whom the principal investigator or sub-investigator considers unsuitable for participation in this study for any other reason.

Design outcomes

Primary

Measure	Time frame
Ulcer reduction rate at 4 weeks	—

Secondary

Measure	Time frame
Scar-stage healing rate	—

Countries

Korea, Republic of

Contacts

Public Contactsoo bin synn

Pusan National University Yangsan Hospital

mk9soo@hanmail.net+82-2-360-1535

Outcome results